Document:

EX-4.15

 Exhibit 4.15 

MSKCC Investigator-Initiated Clinical Trial Agreement with Kazia Therapeutics Limited 

This Agreement (this “Agreement”), effective as of the date of the last signature (“Effective Date”), is entered into by Memorial Sloan
Kettering Cancer Center, a New York not-for-profit corporation (“MSK”), having its principal place of business at 1275 York Avenue, New York, NY 10065, on
behalf of Memorial Hospital for Cancer and Allied Diseases and its Regional Sites (collectively, “MSK”), and Kazia Therapeutics Limited, a drug development company, with its principal office and place of business at Three International
Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000, Australia (“Company”). MSK and Company may each be referred to as a “Party” to this Agreement, and referred to collectively as the “Parties.” 

WHEREAS, Company is a for-profit company that conducts business in the development of
GDC-0084 (“the Study Drug”); and 
 WHEREAS, MSK desires to conduct a clinical study of the Study Drug, as
described in this Agreement, to advance, among other things, scientific and medical knowledge with due regard for patient safety, and has the appropriate facilities and personnel with the necessary qualifications, training, knowledge and experience
to conduct the Study; 
 WHEREAS, MSK, at its election, seeks to conduct the aforementioned clinical study at its Cancer Alliance Clinical Trial Sites, at
local hospitals which are members of MSK’s Cancer Health Equity Research Program, and at local providers under collaborative partnerships with MSK (all collectively hereinafter the “Network Sites”); 

WHEREAS, MSK has prepared a protocol which is of mutual research interest to both MSK and Company; 

WHEREAS, Company has agreed to provide MSK Study Drug and certain funding for the performance of the Study; and 

NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 
  

	1.	 Scope of Work. 

 

	 	1.1.	 Study. MSK agrees to use reasonable efforts to conduct a clinical study entitled, “A Phase I Study
with Expansion Cohort of Concurrent GDC-0084 with Whole Brain Radiation Therapy for Patients with Solid Tumor Brain Metastases Harboring PIK3CA Mutations” (“Study”) as described in the protocol
and any approved amendments thereto (collectively, the “Protocol”), as kept of record by the appropriate Institutional Review Board (“IRB”). A copy of the Protocol, as of the Effective Date of the Agreement, is attached hereto as
Exhibit A, and is incorporated herein by reference. 

  
 1 

	 	1.2.	 Principal Investigator. T. Jonathan Yang, M.D. will serve as the principal investigator (“Principal
Investigator”) for the Study. The Principal Investigator is an employee of MSK and is not a party to this Agreement. 

  

	 	1.3.	 Study Drug. Company will provide MSK with a sufficient quantity of
GDC-0084 (“Study Drug”), presented as GDC-0084 15mg Capsules packed in bottles (unlabeled) as indicated in the Protocol, to conduct the Study at MSK sites, as
well as any other compounds, materials, equipment, and information which the Protocol specifies Company will deliver. MSK will use the Study Drug solely for the purposes of conducting the Study, and will comply with all applicable laws and any
lawful, written instructions provided by Company. MSK must keep the Study Drug secure at all times in accordance with its internal policies and procedures. The Study Drug may only be used in the United States. Any Study Drug, compounds, materials,
and equipment provided by Company that remain after the conclusion of the Study will be either returned to Company or destroyed at Company’s request at the end of the Study, at Company’s sole expense. The Study Drug is not FDA cleared or
approved for marketing, but is described in the Company’s open IND(#112,608). If necessary, MSK will file, or has filed, an Investigational New Drug Application (“IND”) for the Study Drug with the United States Food and Drug
Administration (“FDA”). Upon request from MSK, Company will provide a Letter of Authorization (LoA) to Kazia IND 112,608, to be included with MSK IND submission. MSK will provide a draft copy of the IND to Company, for review prior to
submission to FDA. General responsibilities relating to Study Drug are provided in Exhibit C. 

  

	 	1.4.	 MSK Control. MSK will be the “Sponsor” of the Study as such term is defined in regulations
promulgated by the United States Food and Drug Administration (“FDA”) for clinical studies of the nature of the Study. Except as otherwise expressly described in the Protocol, MSK will have the sole and exclusive authority to conduct,
manage, control and direct the Study, to supervise all MSK personnel participating in the Project, and to manage any MSK subcontractors carrying out MSK responsibilities in the Study; providing, however, Company will have reasonable opportunities
during the course of the Study to advise and consult with the Principal Investigator regarding the Study and its progress. 

  

	 	1.5.	 Performance of Study. MSK represents that it has, or by the commencement of the Study will have, the
experience, capability, and resources, including, but not limited to, sufficient personnel and equipment, to efficiently and expeditiously perform the Study in a professional and competent manner. MSK represents that it and its affiliates and any
other person involved in the conduct of the Study, including, but not limited to, the Principal Investigator, are properly registered with appropriate professional registration bodies to the extent required in New York State. MSK agrees to conduct
the Study in accordance with the terms of this Agreement, the Protocol, MSK policies, applicable ethical standards and all other applicable laws, rules, regulations and guidance. 

  
 2 

	 	1.6.	 Enrollment of Subjects. The Study involves the enrollment of evaluable subjects who meet all of the
Protocol eligibility requirements (“Subject”). No Subject enrollment will occur until there is IRB approval of the Protocol at MSK, and all applicable regulatory approvals have been obtained. 

 

	 	1.7.	 Changes to Protocol. MSK may, from time to time, make changes to the Protocol. Company shall have
reasonable right to review the proposed changes to the extent the change impacts the use of the Study Drug or any change to the budget provided by Company hereunder, and to offer reasonable input prior to IRB submission, unless such changes are
required to manage an urgent safety concern relating to the Study. Any changes to the Protocol will require IRB approval. If these changes will affect the cost of the Study, MSK will submit to Company a written estimate of such change. Any changes
to the Budget (as defined below) which impose additional costs or supply obligations on Company will require Company approval. 

  

	 	1.8.	 Network Sites. In the event one or more Network sites participate in the Study, the Network site(s)
shall have the same rights and obligations of MSK, to the extent applicable, with respect to Sections 4, 5, 6, 7, 8, 9, 10, 11, and 12. 

  

	2.	 Performance Period. The Study shall commence once this Agreement has been duly executed and the Study
has been approved by the IRB and all applicable governmental or regulatory authorities, if any. Unless earlier terminated in accordance with the terms of this Agreement, the Study will continue until the obligations of this Agreement and the
Protocol are completed. 

  

	3.	 Financial Support. 

 

	 	3.1.	 Budget. Company shall provide financial support for the Study in accordance with Exhibit B
attached hereto and incorporated herein by reference, as may be amended between the parties from time to time (“Budget”). Each Party represents that the compensation provided under the terms of this Agreement shall not exceed fair market
value for the activities performed, and has not been determined in consideration of, or in exchange for: (a) any implicit or explicit agreement to provide favorable procurement decisions with regard to Company’s products; or (b) the
value or volume of any business generated between the parties. MSK further represents that the services to be performed under this Agreement do not and will not involve the promotion of a business arrangement or other activity that violates any
state or federal law. 

  

	 	3.2.	 Company will pay to MSK each amount due by Company under the Budget in accordance with sub-section 3.4 provided that: (a) MSK has issued Company a valid tax invoice with respect to the payment before the due date; and (b) MSK has complied with all material obligations under this Agreement.

  
 3 

	 	3.3.	 Any funds paid by Company to MSK under this Agreement must only be used in accordance with this Agreement and
the Budget. MSK must promptly repay to Company: (a) subject to sub-section 13.3, any funds paid by Company to MSK which are unspent as at termination of this Agreement; and (b) any funds paid by
Company to MSK which have been used for a purpose other than in accordance with this Agreement and the Budget. 

  

	 	3.4.	 Payment. Company will pay by check, which will be made payable to Memorial Sloan Kettering Cancer
Center and will be sent to: 

 Sloan-Kettering Institute for Cancer Research 

P.O. Box 29049 

New York, NY 10087 

Attn: Memorial Sloan Kettering Cancer Center, Industrial Affairs 

Tax Identification Number: 13-1624182 

 

	 	3.5.	 No Cost for Study Drug. Company agrees to provide the Study Drug and other Study-related materials
required during the course of the Study at Company’s sole cost and expense, provided that such Study-related materials are: (a) specified in the Budget; and (b) required to conduct the Study in accordance with the Protocol.

  

	4.	 Confidential Information. 

 

	 	4.1.	 Confidential Information. During the Term, either Party may provide proprietary or confidential
information necessary to conduct the Study to the other Party. Accordingly, “Confidential Information” is: (a) data and other information that is disclosed by one Party to the other under this Agreement during the Term and which
relates to the Study, regardless of whether the information is disclosed in writing, orally, graphically, electronically, or in any other manner, but not including Study results; and (b) any information disclosed under this Agreement that is of
a character commonly and reasonably regarded as confidential and/or proprietary in the applicable industry; (c) with respect to Company, includes any information regarding the formulation of the Study Drug to the extent such information is
either marked as confidential or is of a nature that would reasonably be regarded as the confidential and/or proprietary information of Company; and (d) subject to sub-section 4.7, with respect to MSK,
includes Study data and results. Each Party acknowledges and agrees that the other Party reserves all rights in and to their respective Confidential Information. This Agreement shall not constitute a license, assignment, or any other rights,
expressed or implied, to either Party’s Confidential Information, except as expressly provided in this Agreement. 

  

	 	4.2.	 Confidentiality Obligation. All Confidential Information disclosed under this Agreement will be held in
confidence by the receiving Party during the Term of this Agreement and for a period of seven (7) years following termination or expiration of this Agreement. Each Party shall maintain the confidentiality of the other Party’s Confidential
Information with at least the same degree of care as it maintains the confidentiality of its own confidential information, and in any event, not less than a reasonable standard of care. 

  
 4 

	 	4.3.	 Non-Use Obligation. Each Party may disclose the other
Party’s Confidential Information to their affiliates and the directors, officers, employees, contractors, and consultants and its affiliates who have a need to know the Confidential Information, as needed for performance under this Agreement,
and only in connection with and in the furtherance of the Study, after advising each of the obligations under this Agreement, and who are bound by obligations of confidentiality substantially similar to those in this Agreement. Each Party shall be
liable to the other Party for any breach by the receiving Party or its directors, officers, employees, contractors, consultants, and its affiliates. At no time shall either Party use the other Party’s Confidential Information for any purpose
other than as described herein, or disclose such Confidential Information to any third party without the prior written consent of that Party. 

  

	 	4.4.	 Exclusions. The obligations set forth herein shall not apply to any portion of Confidential Information
which: (a) is or later becomes publicly known through lawful means in no violation of this Agreement by the receiving Party; (b) was known or possessed by the receiving Party prior to receipt and without being subject to an obligation to
keep such Confidential Information confidential; (c) is lawfully obtained without restriction from a third party who had the legal right to disclose the same to the receiving Party; or (d) is independently developed by a Party without the
use or benefit of Confidential Information. If either Party is required by applicable law, judicial order or governmental regulation, then that Party will be permitted to disclose (and shall not be required to destroy) any of the other Party’s
Confidential Information that is required to be disclosed by a governmental authority or applicable law in connection with a legal or administrative proceeding (including, but not limited to, in connection with any regulatory approval process),
provided that the Party: (a) notifies the other Party of any such disclosure requirement as soon as practicable; (b) reasonably cooperates with the other Party if the other Party seeks a protective order or other remedy in respect of any
such disclosure; and (c) furnishes only that portion of the Confidential Information which the Party is legally required to disclose. 

  

	 	4.5.	 Return or Destruction. Upon request by either Party, the other Party must destroy or return to that
Party all of their Confidential Information in tangible form, including without limitation all copies, translations, interpretations, derivative works and adaptations thereof. Notwithstanding the foregoing, each Party may retain one (1) copy of
Confidential Information for record-keeping purposes only or as otherwise required by law or regulation. 

  
 5 

	 	4.6.	 Injunctive Relief. Each Party acknowledges that disclosure or improper use of the Confidential
Information may cause the other Party immediate and irreparable harm. Without limiting the following, each Party agrees that the other Party may seek equitable relief in addition to any other remedies available. 

 

	 	4.7.	 Confidential Information in Study Data. Notwithstanding anything in this Section 4, the parties
acknowledge and agree that Company will be entitled to use and disclose Study Data: (a) in accordance with the license provided in sub-section 6.4.1; (b) to regulators to the extent required by law; and
(c) to investors and potential investors to the extent such disclosure will be made under a confidentiality agreement with obligations no less stringent than those binding Company hereunder. Notwithstanding the foregoing, nothing herein shall
be interpreted to supersede MSK’s right to first publish the Study Data under Article 7 hereof. 

  

	5.	 Medical Records. MSK shall make reasonable efforts to ensure that Company is not exposed to any
protected health information of any Study Subject unless required by law or mutual agreement in performance of the Study. In the event Company shall come into contact with any Subject’s medical records, Company shall hold in confidence the
identity of such Subject and shall comply with all applicable law(s) regarding the confidentiality and privacy of such Subject’s records. 

  

	6.	 Proprietary Rights. 

 

	 	6.1.	 Study Data. All information resulting from the Study conducted under this Agreement, including, but not
limited to, all data (including, but not limited to, Subject-level data), results, and conclusions based on such data and/or results (hereinafter “Study Data”) shall be owned exclusively by MSK. 

 

	 	6.2.	 A Clinical Study Report will be supplied to Company by MSK at the conclusion of the Study. If Company requests
access to case report forms and underlying data for the purpose of making submissions to FDA or other competent authorities, MSK and Company shall arrange for appropriate transfer of such information and data (including, but not limited to, any
information necessary to understand such data but excluding any personally identifiable data) in a readable format at Company’s sole expense. MSK agrees to provide reasonable assistance to Company in responding to queries from competent
authorities regarding Study Data, providing that Company agrees to reimburse MSK’s reasonable costs for such assistance if required. 

  

	 	6.3.	 Inventions. “Inventions” shall mean all inventions or discoveries, whether or not patentable,
and all associated intellectual property, which are conceived and reduced to practice in connection with the performance of this Agreement or the Study. MSK shall own all right and title to Inventions and all intellectual property therein.

  
 6 

	 	6.4.	 Licenses. 

  

	 	6.4.1.	 MSK hereby grants to Company a non-exclusive, royalty-free, fully paid,
sublicensable non-transferrable license under MSK’s rights to: (a) subject to MSK’s publication rights in Section 7, the Study Data; and (b) Inventions that are conceived and reduced
to practice in performance of the Study through the use of the Study Drug (“Study Drug-Related Inventions”). 

  

	 	6.4.2.	 Provided Company has otherwise performed its material obligations under this Agreement , MSK grants to Company
an option to negotiate an exclusive license to MSK’s rights to Study Drug-Related Inventions (“Option”). Company must exercise such Option with respect to a Study Drug-Related Invention no more than ninety (90) days after
Company’s receipt of the applicable invention disclosure from MSK (“Option Period”). The Parties shall use their reasonable efforts to negotiate, for a period not to exceed ninety (90) days after Company’s exercise of such
Option, a definitive license agreement satisfactory to both Parties (“Negotiation Period”). In the event Company fails to exercise its Option within the Option Period, or the Parties fail to reach a definitive agreement on the terms of
such definitive license within the Negotiation Period or such other period of time agreed by the Parties, MSK shall have no further obligation to Company under this Agreement with respect to an exclusive licence to said specific Study Drug-Related
Inventions. Any license negotiated pursuant to this Section shall reserve for MSK a non-exclusive license to practice the Study Drug-Related Invention for non-commercial
research, academic, and patient-care purposes, and for publication purposes in accordance with the terms of Section 7 (Publications). 

  

	 	6.5.	 No License. Neither Company nor the MSK transfers to the other by operation of this Agreement any patent
right, copyright right, or other proprietary right of any party, except as explicitly set forth in this Agreement. 

  

	7.	 Publications. MSK reserves the right to make or permit to be made scholarly disclosures of the results
of the Study, including without limitation, publication in scholarly journals, presentations at academic and other conferences, disclosures to MSK and non-MSK scholars, and disclosures in grant and funding
applications. At least thirty (30) days prior to any such publication, MSK shall share with Company a manuscript of the proposed publication for their reasonable review. MSK must limit the use of any Company Confidential Information in any
publication to the extent reasonably practicable and consistent with principles of academic freedom. If Company identifies its Confidential Information contained in the proposed publication, MSK will remove such Company Confidential Information to
the extent such removal does not render the publication or presentation inaccurate or misleading. In the event that the Publication discloses any registrable intellectual property of Company, MSK agrees to further delay release of such publication
or presentation for an additional forty-five (45) days so that Company can seek legal protection of such registrable intellectual property subject matter. MSK will provide, in accordance with customary standards, an appropriate acknowledgement
in any such publication of Company’s support or other role in the Study. Despite any license granted in this Agreement, Company must not publish any Study Data in any scholarly journal until the earlier of: (a) the date after MSK publishes
such Study Data in a scholarly journal; or (b) the date which is 18 months from completion of the Study. 

  
 7 

	8.	 Use of Name. Except as otherwise required by law or regulation, or as permitted under Section 7
(Publication), neither Party shall release or distribute any materials or information containing the name of the other Party or any of its employees without prior written approval by an authorized representative of the
non-releasing Party, but such approval shall not be unreasonably withheld. Notwithstanding anything to the contrary, each Party agrees to allow use of the name or marks of that Party or any of its affiliates,
departments, directors, officers, employees, or agents: (a) as permitted under Section 7 (Publications); (b) as required by applicable law, judicial order or governmental regulation; or (c) to the extent used in reference to
information that is already in the public domain. 

  

	9.	 Conformance with Law and Accepted Practice. 

 

	 	9.1.	 Compliance. The Parties will engage under this Agreement, to the extent applicable to each Party, in
compliance with all applicable laws, regulations, and guidance, including, without limitation, to the extent applicable: (a) the United States Food, Drug and Cosmetic Act (“FDCA”); (b) regulations and guidance of the FDA governing
clinical investigators and the protection of human subjects; (c) the Federal Common Rule, as set forth in 45 C.F.R. Part 46; (d) export control and economic sanctions regulations that prohibit the shipment of United States-origin products and
technology to certain restricted countries, entities and individuals; (e) United States anti-bribery laws pertaining to interactions with government agents, officials and representatives; and (f) the Health Insurance Portability and
Accountability Act of 1996 (HIPAA). If generally accepted standards of GCP relating to the safety of Subjects require a deviation from any Protocol, these standards will be followed. Any Party who receives notice of the need for a deviation from the
Protocol will promptly inform the other Party to this Agreement of the facts causing the deviation as soon as the facts are known to the Party. In addition, MSK will ensure that Principal Investigator will promptly inform the applicable IRB of the
deviation. In the event of a conflict between any of the terms of this Agreement and applicable law, compliance with the latter shall never constitute a breach of this Agreement. 

 

	 	9.2.	 Debarment. Each Party represents that it, nor, to the best of its knowledge, any of its employees or
agents contributing to the performance of its obligations hereunder, is not presently nor has ever been: (a) debarred pursuant to Section 306 of the FDCA, as amended; (b) disqualified as a clinical investigator pursuant to 21 C.F.R.
§ 312.70; (c) excluded from participation in any “federal health care program” as defined in 42 C.F.R. § 1001.2 (as indicated by an appearance on the List of Excluded Individuals/Entities maintained by the Office of Inspector
General of the Department of Health and Human Services, the Excluded Parties List System maintained by the U.S. General Services Administration, or other applicable exclusionary databases); or (d) debarred by an applicable state law. MSK agrees
not to knowingly employ or otherwise engage any individual or entity for the performance of this Study who has been debarred, disqualified, or excluded, as described above. In the event of any debarment occurring during the period of this Agreement,
such Party shall immediately provide notice to the other Party. 

  
 8 

	 	9.3.	 Required Notification. Pursuant to AAHRPP requirements, during and for a period of at least two
(2) years after the completion of the Study, Company shall promptly report to the Principal Investigator any information regarding the Study Drug that it reasonably believes could be determined to: (a) affect the safety and welfare of
Study Subjects; or (b) affect the willingness of Study Subjects to continue their participation in the Study; or (c) that may alter the IRB’s approval to continue the Study. MSK, through the Principal Investigator and/or IRB, as
appropriate, shall be responsible for informing Study Subjects of the above important information they learn from Company. This Section survives the expiration or termination of this Agreement. 

 

	 	9.4.	 Registration. To the extent required by law, MSK shall register the Study with the public registry
clinicaltrials.gov prior to enrolling the first patient in the Study, and shall comply with all requirements thereafter to keep the registration accurate and up-to-date.

  

	 	9.5.	 Safety Reporting. Notwithstanding any other provision of this Agreement, MSK shall notify Company of any
suspected unexpected serious adverse reactions (“SUSARs”) during the course of the Study, within one (1) business day of MSK first becoming aware of their occurrence, so that Company may fulfil its regulatory reporting requirements.
In addition, MSK shall provide quarterly safety listings, in a format mutually acceptable and consistent with common practice, so that Company may include them in its mandatory data filings. 

 

	10.	 Responsibility and Insurance. 

 

	 	10.1.	 Responsibility. 

 

	 	10.1.1.	 Each Party shall be responsible for any liabilities arising out of its own respective acts in performing its
respective obligations under this Agreement. On the one hand, Company shall be responsible for liabilities arising from manufacture, design, and formulation of the Study Drug and for any use of data, results, and intellectual property granted by
Institution to Company hereunder. On the other hand, Institution shall be responsible for liabilities arising from treatment of Study subjects enrolled under the Protocol. 

  
 9 

	 	10.1.2.	 No Party enter into an agreement, settlement or otherwise resolve any claim that involves an admission of
liability, financial responsibility, or wrongdoing by, or imposes any obligations on the other Party without the prior written consent of the other Party, which consent will not be unreasonably withheld. 

 

	 	10.2.	 Subject Injury. MSK will provide medical treatment to Study Subjects who suffer an injury and/or
condition as a result of the Study. Company will pay for all costs associated with all such medical treatment of any injury and/or condition that is a result of the Study subject’s participation in the Study, the use of the Study Drug and/or
the performance of any intervention required by the Protocol solely to the extent such injury or condition is the result of Company’s manufacturing defect of the Study Drug. Company shall not be responsible for paying for any such cost of any
such medical treatment if any such injury and/or condition is determined to result directly from (a) the negligence, recklessness, or intentional misconduct of, or violation of law by, MSK or any of its associates, affiliates, or personnel
performing the Study; (b) failure of MSK or any of its associates, affiliates, or personnel performing the Study to adhere to the terms of the Protocol, provided that emergency medical care shall not be deemed a violation of the Protocol.

  

	 	10.3.	 Insurance. Company shall maintain general liability insurance, including products liability or clinical
trial coverage, sufficient to meet its indemnification obligation under this Agreement. Company agrees that the limits of such coverage will be at least $5,000,000 per occurrence and $10,000,000 in the aggregate. Such insurance must include MSK,
MSK’s IRB, and its affiliates as additional insureds with respect to this Agreement. This insurance shall be written to cover claims incurred, discovered, manifested, or made during or after the expiration of this Agreement. Company will
provide a certificate of insurance and additional insured endorsement evidencing such coverage upon MSK’s request. Company will provide written notice to MSK at least thirty (30) days prior to the cancellation, non-renewal, or any material change to such insurance. The amount of Company’s insurance coverage shall not be construed as creating a limit on Company’s indemnification obligations under this Agreement.

  

	11.	 Representations and Warranties. 

 

	 	11.1.	 Representations. 

 

	 	11.1.1.	 Each Party represents that as of the Effective Date, there is no hindrance, by law or agreement, preventing it
from entering into this Agreement or from performing its obligations under this Agreement. This Agreement has been duly executed and delivered by each Party and is enforceable against it in accordance with the Agreement’s terms. Each Party
shall perform its obligations under this Agreement in a professional and diligent manner and in compliance with all applicable laws, rules and regulations. 

  
 10 

	 	11.1.2.	 Company further represents that: (a) it has obtained all necessary governmental and regulatory approvals
to perform its obligations under the Agreement and provide the Study Drug; (b) such approvals will be in full force and effect during the Study; (c) Study Drug has been manufactured, formulated and passed quality control tests in
accordance with Company IND 112,608 and applicable regulations; (d) it has disclosed to MSK and applicable government authorities all relevant, material information concerning the safety, use, efficacy and Study Drug experience; (e) use of
the Study Drug for Study purposes will not infringe the rights, patent or otherwise, of any third party; and (f) any hazardous material packaging provided by Company meets regulatory requirements for MSK’s use according to the Protocol.

  

	 	11.1.3.	 Except as expressly set out in this Agreement, MSK makes no representations or warranties, regarding the Study,
including, but not limited to, the data and/or results of the Study or the ownership, merchantability, or fitness for a particular purpose of such data, results or Inventions. 

 

	12.	 Limitation of Liability. The Parties acknowledge and agree that neither Party shall be liable to the
other, or to anyone claiming through such other Party, for any losses or damages arising under any of the following: 

  

	 	(a)	 loss of anticipated opportunity, revenue, savings, profit or goodwill; or 

 

	 	(b)	 any indirect, consequential, incidental, punitive or exemplary damages, however caused, and whether arising
under contract, tort (including but not limited to, negligence) or otherwise. 

  

	13.	 Term; Termination; Survival. 

 

	 	13.1.	 Term. This Agreement commences on the date of the last signature on the signing page (“Effective
Date”) and continues until the earlier of the completion of the Study or five (5) years after the Effective Date (“Term”), unless earlier terminated in accordance with this Agreement. 

 

	 	13.2.	 Termination. This Agreement may be terminated: 

 

	 	(a)	 by MSK for any reason with thirty (30) days written notice to Company; 

 

	 	(b)	 by either Party by written notice to the other immediately in the interest of Study subject safety;

  

	 	(c)	 by either Party upon the material breach of the other Party, provided that the Party alleging such breach has
given written notice of same and the breach has not been cured within forty-five (45) days from the delivery of such written notice; 

  
 11 

	 	(d)	 upon the occurrence of an event qualifying as a termination event as described in the Protocol;

  

	 	(e)	 by either Party upon forty-five (45) days’ notice to the other Party in the event the terminating
Party becomes insolvent, makes or has made an assignment for the benefit of creditors, is the subject of proceedings in voluntary or involuntary bankruptcy instituted on behalf of or against such Party (except for involuntary bankruptcies which are
dismissed within sixty (60) days), or has a receiver or trustee appointed for substantially all of its property; or 

  

	 	(f)	 by the Company upon forty-five (45) days’ notice to MSK in the event that the Company’s Board of
Directors formally resolves that financial support of the Study is no longer commercially reasonable nor consistent with the exercise of prudent scientific and business judgment, including, but not limited to, taking into account the interests of
Company’s shareholders. Under such circumstances, MSK and Company shall negotiate in good faith opportunities to modify or otherwise fund the Study. Notwithstanding the foregoing, in the event of any termination by Company under this
Section 13.2(f), Company will ensure that Study Drug supply continues to be provided to MSK to ensure that patients who are currently receiving treatment in the Study are able to complete their treatment as per the Protocol.

  

	 	13.3.	 Early Termination. In the event of such early termination by Company, Company will reimburse MSK for all
expenses reasonably incurred up to the date of termination which Company would be required to fund in accordance with the Budget, including, but not limited to, all non-cancelable obligations, and shall pro-rate financial support due based upon actual work performed and expenses committed pursuant to the Study. 

  

	 	13.4.	 Survival. Termination of this Agreement by either Party shall not affect the rights and obligations of
the Parties accrued prior to the effective date of the termination. The rights and duties under the following Sections: Financial Support, Confidential Information, Proprietary Rights, Publication, Use of Names, Conformance with Law and Accepted
Practice, Indemnification and Insurance, Representations and Warranties, Limitation of Liability, Termination, Construction, Severability, Waiver, Governing Law, Independent Contractors, Third Party Beneficiaries, Notice, and Entire Agreement;
Counterparts will remain in effect. 

  

	14.	 Amendments. No amendment or modification of this Agreement will be effective unless in writing and
signed by both Parties. 

  
 12 

	15.	 Construction. In construing this Agreement, unless expressly specified otherwise: (a) except where
the context otherwise requires, use of any gender includes any other gender, and use of the singular includes the plural and vice versa; (b) headings and titles are for convenience only and do not affect the interpretation of this Agreement;
(c) each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms of this Agreement, the Parties
agree that no presumption will apply against the Party that drafted such terms. 

  

	16.	 Severability. In the event any provision of this Agreement is illegal, invalid, or unenforceable, in
whole or in part, under applicable law, such provision will be ineffective to that extent only and shall be restated to reflect the original intentions of the Parties as nearly as possible in accordance with applicable laws. The legality, validity,
and enforceability of the remaining provisions shall not be affected thereby, and shall remain in full force and effect. 

  

	17.	 Assignment. Neither Party may assign or transfer this Agreement or services to be performed under this
Agreement without the prior written consent of the other Party. 

  

	18.	 Waiver. No action or inaction by either Party shall be construed as a waiver of such Party’s rights
under this Agreement or as provided by applicable law. No term of this Agreement may be waived except by an express agreement in writing signed by the waiving Party. The failure or delay of a Party in enforcing any of its rights under this Agreement
shall not be deemed a continuing waiver of such right. The waiver of one breach hereunder shall not constitute the waiver of any other or subsequent breach. 

  

	19.	 Governing Law. This Agreement shall be governed by the laws of the State of New York without regard to
its conflicts of law principles, and Parties agree to the exclusive jurisdiction and venue of the state and federal courts in New York County, New York (without restricting any rights of appeal). Each Party agrees that all claims and matters may be
heard and determined in any such court and each Party waives any right to object to such action on venue, forum non conveniens, or similar grounds. 

  

	20.	 Subcontracting. MSK collaborates with a network of affiliated alliance sites, regional network sites,
underserved minority populations and community health clinics (collectively, “Network Sites”). For avoidance of doubt, Network Sites include Regional Network Sites, MSK Alliance Clinical Trial Sites, and Cancer Health Equity Research
Program Sites. On MSK’s behalf, Company shall supply to Network Sites (or procure the supply) at no cost, quantities of Study Drug required for conducting the Study in accordance with the Protocol and applicable laws. MSK will be responsible to
Company for any act or omissions of all Network Sites relating to the Study and Study Drug as if such acts or omissions were those of MSK. 

  

	21.	 Independent Contractors. The relationship of the Parties hereto is that of independent contractors.
Neither Party hereto shall be deemed to be an agent, partner, employee or joint venturer of the other for any purpose as a result of this Agreement or any transaction contemplated by this Agreement. Neither Party hereto shall have any express or
implied right or authority to assume or create any obligation on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any third party. 

  
 13 

	22.	 Third Party Beneficiaries. Except as otherwise specifically set forth, this Agreement does not create
any rights, or rights of enforcement, in third parties. 

  

	23.	 Notice. Any notice given pursuant to the terms and provisions hereof will be in writing and delivered by
hand, courier, or by a postage-paid traceable method of delivery to the address below: 

 If to MSK: 

 

							
	Memorial Sloan Kettering Cancer Center	  			
	1275 York Avenue, Box 524	  			
	New York, N.Y. 10065	  			
	 Attention:
	  	Gregory Raskin, M.D.	  			
		  	Vice President	  			
		  	Technology Development	  			

 With a Copy to: 

 

							
	Memorial Sloan Kettering Cancer Center	  			
	Office of Technology Development	  			
	Attention:	  	Shilpi Banerjee, Esq., Ph.D.	  			
		  	Chief Intellectual Property Counsel	  			
	If by mail:	  	1275 York Avenue, Box 524	  			
		  	New York, N.Y. 10065	  			
	If by courier:	  	600 Third Avenue, 16th Fl.	  			
		  	New York, NY 10016	  			

 If to Company: 

Kazia Therapeutics Limited 

Three International Towers 

Level 24, 300 Barangaroo Avenue 

Sydney NSW 2000, Australia 
  

	24.	 Force Majeure. Neither Party will be responsible or liable for any delay in performance of any of the
terms or conditions required by this Agreement due to conditions beyond the delayed Party’s reasonable control. Each Party will, however, use its reasonable efforts to avoid or cure such conditions. The Party claiming such conditions as an
excuse for delayed performance will give prompt written notice to the other Party of the conditions, its intent to delay performance, and how long the delayed Party expects the delay to last. The delayed Party will resume its performance as soon as
performance is possible. 

  

	25.	 Entire Agreement; Counterparts. 

  
 14 

	 	25.1.	 Entire Agreement. This Agreement embodies the entire agreement of the Parties. It supersedes all prior
agreements between the Parties with respect to the subject matter. In the event of any inconsistency between this Agreement and the Protocol, the Protocol takes precedence in matters of medicine and science, and this Agreement takes precedence in
all other matters. 

  

	 	25.2.	 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original,
but all of which, together, shall constitute the same instrument. Execution and delivery of an executed signature page to this Agreement in PDF file format, or by electronic mail shall be as effective as delivery of a manually signed counterpart of
this Agreement. 

 [SIGNATURES ON FOLLOWING PAGE] 

  
 15 

 IN WITNESS WHEREOF, this Agreement is executed as of the Effective Date by a duly authorized
representative of each of MSK and Company. 
  

									
	MEMORIAL SLOAN KETTERING CANCER CENTER	  		  		  	
					
	By:	 	                                     
                       	  		  		  	
				
	Print Name: Gregory Raskin, M.D.	  		  		  	
				
	Title: Vice President, Technology Development	  		  		  	
				
	Date: 18 July 2019	  		  		  	
				
	KAZIA THERAPEUTICS LIMITED  
	  		  		  	
	By:	 	                                     
                       	  		  	By:	  	                                     
                       
			
	 Print Name: Dr James Garner 
 Title: Director

 
 Date: 22 July 2019
	  		  	 Print Name: Kate Hill 
 Title: Company Secretary

 
 Date: 22 July 2019

 READ AND UNDERSTOOD BY 

T Jonathon Yang 
 Tzu-l
Jonathon Yang, MD, PhD 
 Principal Investigator 
 Date:
18 July 2019 

  
 16 

 Exhibit A – Protocol 

(Incorporated by reference) 

  
 17 

 Exhibit B – Study Budget & Payment Schedule 

 

									
	 Execution of contract and IRB approval
	  	 	20.00	% 	 	 	                	 
	
First patient dosed to Part A
	  	 	15.00	% 	 	 	 	 
	
Completion of Part A (escalation)
	  	 	30.00	% 	 	 	 	 
	
First patient dosed to Part B
	  	 	15.00	% 	 	 	 	 
	
Last patient in
	  	 	10.00	% 	 	 	 	 
	
Final Study Report
	  	 	10.00	% 	 	 	 	 
	
Total Budget
	  	 	100.00	% 	 	 	 	 

 1. Payments will be issued within 30 days of receipt of invoice. Payments must clearly identify invoice number,
protocol identifier, and MSK PI. 
 2. If full enrollment is not achieved, payments will be made for all expenses reasonably incurred to the
date of termination in accordance with the Budget and with the terms of the Agreement. 

  
 18 

 Exhibit C– Study Drug Responsibilities 

Study Drug Responsibilities 

GDC-0084 Capsules – Phase 1 Clinical Study Use 

Background & Scope: 
  

	 	(i)	 MSK plan to Sponsor a Phase 1 clinical study using GDC-0084, with study
drug responsibilities as indicated below. 

  

	 	(ii)	 Company (Kazia) will supply to MSK GMP manufactured and primary packed study drug for Phase 1 clinical trial
use in the US. Company (Kazia) responsibilities as indicated below. 

  

							
				
	 #
	  	 Responsibility
	  	Company
(Kazia)	  	MSK
	 1
	  	Study Drug: Supply of GMP manufactured and primary packed (unlabeled) GDC-0084 15mg capsules with supporting GMP documentation (e.g. manufacturers CoA)	  	X	  	
				
	 2
	  	Study Drug: Each bottle of study drug supplied will be identified (either labeled or ink-jet printed) with a unique lot number to prevent risk of
mix-up	  	X	  	
				
	 3
	  	Retest Date & Storage Conditions: Provision of retest date and storage conditions for the study drug supplied	  	X	  	
				
	 4
	  	Ordering: Requests for study drug will be provided to Kazia in writing	  		  	X
				
	 5
	  	Shipping: Will ship study drug to MSK accompanied by relevant paperwork (e.g. packing list)	  	X	  	
				
	 6
	  	Receipt & Labeling: Receive, store and label study drug for clinical study use	  		  	X
				
	 7
	  	Release of Study Drug: responsibility for release of labeled study drug for Phase 1 clinical study use in US	  		  	X
				
	 8
	  	Product Defects / Product Complaints: will promptly notify the other party if a Quality Defect is observed or reported (e.g. damage to capsules or primary packaging)	  	X	  	X
				
	 9
	  	Product Recall: will notify MSK in the event of a Product Recall and both parties will work together as may be required to coordinate the Recall and notify the relevant regulatory authorities [Note: Product Recall may also
be referred to as “stock recovery” in US as the Sponsor exerts direct control over the drug].	  	X	  	
				
	 10
	  	Returns & Destruction: Responsibility for any returns and destruction rests with	  		  	X

  
 19EX-4.16

 Exhibit 4.16 

INVESTIGATOR INITIATED CLINICAL TRIAL AGREEMENT 

This Investigator Initiated Clinical Trial Agreement (“Agreement”) is made as of the 18th
September 2020 (“Effective Date”) between Kazia Therapeutics Limited (ACN 063 259 754) a company incorporated in Australia with a principal place of business at L24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (“Company”),
and Dana-Farber/Partners Cancer Care, Inc., a collaboration among Dana-Farber Cancer Institute, The Brigham and Women’s Hospital, Inc. and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a
not-for-profit tax-exempt corporation organized under the laws of the Commonwealth of Massachusetts with its principal place of
business at 450 Brookline Ave., Boston, MA 02215 (“Institution”) each referred to herein individually as a “Party” and collectively as the “Parties”. 

The Parties to this Agreement share a common mission of improving the public health by engaging in research for the purpose of discovering and making
available to the public new and improved medical drugs, devices, procedures, and information. In connection with this mission, Company desires to have further clinical research conducted on its Drug described below. Institution, through
Dr. Lakshmi Nayak (“Principal Investigator”), having particular expertise and opportunity, desires to provide this research. 

Accordingly, for good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows: 

Section 1: Study Performance 

1.1    Conduct of Study in Accordance with Protocol; Priority of Terms. Subject to the initial and continuing
approvals described in Section 1.2 below, Institution, through Principal Investigator, agrees to conduct a clinical study of paxalisib (GDC-0084) (“Study Drug”) in accordance with the
study protocol entitled “A Phase 2 study of Paxalisib (GDC-0084) in recurrent or refractory Primary Central Nervous System Lymphoma (PCNSL).” attached to this Agreement as Exhibit A and
herein incorporated by reference (“Study”). The Parties to this agree that the Study will be performed in strict accordance with the Study protocol entitled above, and any subsequent amendments thereto (the “Protocol”),
applicable federal, state, and local laws, regulations and guidelines, and good clinical practices as required under FDA regulations (“GCPs”). In the event of any conflict between the Protocol and the provisions of the main body of this
Agreement, the Protocol shall govern with respect to scientific, Study management and reporting and subject consent issues, and the provisions of the main body of this Agreement shall govern with respect to all other issues. 

1.2    Study Review and Approvals. The Study shall be conducted by personnel, agents, vendors, or consultants of
Institution under the direction of the Principal Investigator at Institution or additional facilities with the prior approval and ongoing review of all appropriate and necessary review authorities. Institution, through Principal Investigator, shall
provide Company with written evidence of review and approval of this Study by Institution’s Institutional Review Board (“IRB”) prior to the initiation of the Study and shall inform Company of the IRB’s continuing reviews of the
Study promptly after each such review takes place, which shall be at least once per year. Initiation of the Study Protocol shall not begin until IRB approval is obtained. Institution may make any material amendment(s) to the informed consent form if
Institution is so expressly directed by Institution’s IRB. A “material amendment” is any amendment to conform with Institution’s obligations under 45 CFR Pt. 46.116 (a) (2) and 21 CFR Pt. 50.25. In accordance with the
obligations under the Food and Drug Administration Amendment Act of 2007 (“the ACT”), Institution agrees to register this clinical trial with the public registry clinicaltrials.gov before enrollment of the first patient at Institution and
comply with all of the Acts requirements thereafter. Additionally, Institution will be exclusively responsible for updating and/or amending such registration as appropriate. Institution is responsible for IND submission. Company will provide to
Institution a Letter of Authorization (LoA) to cross-reference the Company IND and Company requests the opportunity to review the Institution IND prior to FDA submission. 

 1.3    Completion of the Study. For purposes of this Agreement,
Company and Institution shall consider the Study to be complete and concluded at all sites at such time as achievement of the primary endpoint is reached or as otherwise specified in the Protocol (“Study Conclusion”). 

1.4    Provision and Use of Study Drug. Company shall be responsible for providing and delivering to the research
pharmacy of each site of Institution, at no charge, sufficient quantities of the labeled Study Drug (paxalisib 15mg Capsules, bottled and identified with lot number) as may be required for the Study in accordance with the Study schedule.
Institution, through Principal Investigator, will safeguard such Study Drug with the degree of care used for its own property and shall return or otherwise dispose of any remaining Study Drug at the Study Conclusion in accordance with Company’s
instructions and Institution’s pharmacy’s Standard Operating Procedures (SOP’s) for drug destruction. Institution and Principal Investigator shall not use any Study Drug for any purpose other than the Study, unless otherwise agreed.
Company represents and warrants that it is in compliance with federal, state, and local laws and regulations relating to the manufacture and formulation of any investigational drug and to any other materials supplied, and with all applicable legal
requirements. Responsibilities between the Parties are provided in Exhibit C. 
 Section 2: Data and Safety Monitoring Plan and
Reports; Material Subject Information 
 Company agrees to notify Principal Investigator in writing promptly (no later than 30 days) of
information (such as Study Drug results or findings from other studies involving Study Drug), including results obtained for a period of two (2) years after completion or closure of the Study that could affect the safety or medical care
of subjects who were at any point enrolled in the Study, influence the conduct of the Study, or alter the IRB’s approval. Company and Institution shall comply with, and nothing herein shall limit, their respective reporting requirements to
regulatory authorities, including, for example, the Food and Drug Administration, the Office for Human Research Protections, and others as required. Institution, through the Principal Investigator and/or IRB as appropriate, shall be responsible
for informing subjects of the above important information they learn from Company in accordance with the IRB-approved informed consent form and Company shall not contact them. No other provision of this
Agreement shall be construed to override the provisions of this Section 2. 
 In addition, Institution shall notify Company of any
suspected unexpected serious adverse reactions (“SUSARs”) during the course of the Study within 24 hours of Institution receiving notification of their occurrence, so that Company may fulfil its regulatory reporting requirements.
Institution shall reasonably support any necessary follow-up of SUSARs. In addition, Institution shall provide quarterly safety listings to Company, in a format mutually acceptable, for inclusion in its
mandatory regulatory filings. 

 Section 3: Study Data/Results 

3.1    Provision of Data/Results. 

(a)    A Clinical Study Report will be supplied to Company by Institution at the conclusion of the Study. Company shall
have the right to use data produced in the performance of the Study (“Data”) for all lawful purposes in accordance with Section 3.2. If Company requests, full access to the case report forms and underlying data for the purpose of
making any submission to the Food and Drug Administration and other foreign health authorities, Institution and Company shall arrange for further transfer at Company’s expense. If Company wishes to file the Study Data with the FDA or other
health authority at some time in the future, Institution agrees to provide reasonable assistance to Company for such activities, including responding to questions about the Study Data and Company and Institution shall negotiate a budget for payments
to support the work necessary for Institution to provide the requested assistance/information to Company. Company acknowledges and agrees that in no event is Institution responsible for formatting or
re-formatting the Data so as to be acceptable for submission to the FDA or other regulatory agencies, unless separately negotiated and agreed between Company and Institution. 

(b)     Institution shall own the data from its Study, its medical records and Institution-issued research notebooks. 

3.2    Use of Data/Results. Institution shall comply in all material respects with all applicable federal, state
and local laws and regulations regarding the privacy of individually identifiable health information (including its collection, use, storage, and disclosure), including, but not limited to Health Insurance Portability and Accountability Act of 1996
(“HIPAA) and the regulations promulgated thereunder, as may be amended from time to time. Company may receive individually identifiable health information subject data regarding serious adverse events and patient’s response to therapy.
Therefore, Company agrees to use and disclose individually identifiable health information only in a manner consistent with applicable federal, state and local laws and regulations regarding the privacy of individually identifiable health
information, including, but not limited to the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and the regulations promulgated thereunder, as may be amended from time to time and any applicable subject authorization,
including the terms and conditions of the informed consent executed by the patient, or as otherwise may be required by applicable law. Company may use information that is not identifiable under any applicable U.S. laws for any research and
development purpose. Company will use all reasonable efforts to protect the privacy and security of individually identifiable health information and will require its business partners to do so also. Company will not contact any Study subjects,
unless permitted by the informed consent form. The Parties to this Agreement agree that all protections, ownership rights and use restrictions afforded by this Agreement to the health information and data of research subjects enrolled in the Study
will apply equally to any health information or other data collected from such research subjects’ pregnant partners, if any and regardless of when during the Study the partner becomes pregnant, whether or not a pregnant partner is formally
recognized by the IRB as being a human research subject enrolled in the Study. No other provision in this Agreement shall be construed to override the provisions of this Section 3.2. 

 Section 4: Publication 

4.1    Principal Investigator shall be free to publish the data/results of the Study subject only to the provisions of
Section 8 regarding Company’s Proprietary Information. The Institution shall require Principal Investigator to furnish Company with a copy of any proposed publication prior to submission for publication, at least thirty (30) days
prior to submission for manuscripts and at least seven (7) days prior to submission for abstracts. Company shall be entitled to review such proposed publications solely for the purpose of identifying Company Proprietary Information, which shall
be removed from the publication upon Company’s request to the extent such deletion does not preclude the complete and accurate presentation and interpretation of the Study results; and to identify any patentable Inventions, which shall be
addressed as described below; and to provide any other comments Company desires to provide, provided that Principal Investigator shall have no obligation to address any such additional comments. At the expiration of such thirty (30) day or
seven (7) day period, Principal Investigator may proceed with submission for publication provided that any identified Company Proprietary Information has been removed; and provided further that upon notice by Company that Company reasonably
believes a patent application claiming an Invention (as defined in Section 5) should be filed prior to such publication, in Institution’s discretion such submission shall be delayed for up to an additional sixty (60) days or until any
patent application or applications have been filed, whichever shall first occur. In no event shall the submission of such publication of results be delayed for more than ninety (90) days for manuscripts and for more than sixty-seven
(67) days for abstracts from the date such proposed publication was provided to Company; at the end of said ninety (90) or sixty-seven (67) days, the Principal Investigator shall be free to publish such results as proposed. 

4.2    Nothing herein shall be construed to restrict disclosure of results by Institution and Principal Investigator as
necessary for patient and public safety concerns, to prevent an immediate hazard to the safety, rights or welfare of patients or the public and/or for regulatory compliance. 

Section 5: Inventions/Intellectual Property 

5.1    Invention. It is expressly agreed that neither Company nor Institution transfers by operation of this
Agreement to the other party any patent right, copyright, or other proprietary right either party owns as of the Effective Date. Institution will promptly and fully disclose in writing to Company any inventions in the performance of the Study as
outlined in the Protocol (“Invention”). “Company Invention” means Invention that relate to the Study Drug. Institution will promptly and fully disclose in writing to Company, Company Invention. 

 

	 	a.	 Option for Exclusive Commercialization License for Company Invention. Subject only to any non-exclusive license retained by the U.S. Government or any non-profit organization providing funding for the Study, Institution grants to Company an option to obtain an
exclusive, royalty-bearing and sublicensable license to Institution’s interests, if any, in any Company Invention conceived of within one (1) year of the Study Conclusion and Company’s receipt of the final study report or draft
manuscript, to use such Company Invention for research purposes and to make, use and sell (or otherwise commercialize) any such Company Invention or any products that are covered by patent rights that claim or that include any such Company
Invention. This option is to be exercised by written notice to Institution during said three month period and the negotiation, during the three (3) months next following such notice, of a license agreement containing license terms standard for
agreements between universities and industry including without limitation clauses providing for payment of reasonable royalties and other compensation to Institution, objective, time-limited due diligence provisions for the development,
commercialization and marketing of a product embodying the Invention and product liability indemnification and insurance requirements which are acceptable to Institution’s liability insurance carrier. In the absence of such notice by Company
and agreement on license terms, Institution may grant a license to such Patent Rights to any other party 

	 	b.	 Non-Exclusive Licenses. Institution grants to Company the
following rights which Company may sublicense to its Invention and/or marketing collaborators: 

  

	 	(i)	 Improvements. A perpetual, non-exclusive, royalty-free
license to Institution’s interest in Invention which are “improvements” of the Study Drug(s). 

  

	 	(ii)	 New Uses. A perpetual, non-exclusive, royalty-free license to
Institution’s interest in Invention which are “new uses” of the Study Drug(s). 

  

	 	c.	 Patent Applications. 

Any patent applications necessary to protect the interests of the parties in any Company Invention made solely by Institution will be prepared,
filed, and prosecuted by Institution. Any patent applications necessary to protect the interests of the parties in any Company Invention made jointly by Institution and Company or will be prepared, filed and prosecuted by Company. All patent costs
pertaining to any patent rights filed by mutual agreement of Company and Institution, including preparation, filing, prosecution, issuance and maintenance costs, shall be borne by Company. 

5.2    All information given to Company by Institution in accordance with Section 5.1 will be held in confidence by
Company so long as such information remains unpublished or publicly undisclosed by Institution. 
 Section 6: Use of Name 

Except for disclosure by Institution of Company’s support for the Study in publications, for purposes of recruitment/consent of Study
subjects, and for purposes of meeting any applicable requirements for the registration of the Study or of Study results with a publicly accessible or other clinical trial registry, neither Party to this Agreement shall use the name of the other
Party or of any staff member, employee, student, or agent of the other Party or any adaptation, acronym or name by which the other Party is commonly known, in any advertising, promotional or sales literature or in any publicity without the prior
written approval of the Party or individual whose name is to be used. 

 Notwithstanding this, it is acknowledged that Company, as a publicly-listed company, may be
required to disclose the existence of this agreement in mandatory filings to regulatory bodies, including, without limitation, the Securities and Exchanges Commission, NASDAQ, and the Australian Securities Exchange. Company shall make reasonable
efforts to notify Institution in advance of any such disclosures wherever possible, and Institution shall have the right to request reasonable amendments or redactions to any such disclosures. 

Section 7: Audits, Study Records 

Any audits or on-site visits conducted by Company will be undertaken in conjunction with Institution,
at reasonable times and with reasonable prior notice, and pursuant to guidelines established by Institution in order to assure patient confidentiality. If Company gains access to any protected health information of a Study subject that is not
covered by the informed consent form, Company shall hold such information in the strictest confidence, shall not remove records containing such information from the Institution and, if inadvertently removed, shall return any records containing such
information to the Institution as soon as practicable. If in connection with the Study or performance of this Agreement Company and/or any of its agents, employees, officers or representatives come into contact with individually identifiable health
information relating to patients of Institution who are not Study subjects, Company agrees to, and agrees to ensure its agents, employees, officers or representatives agree to, maintain the strictest confidentiality of such information and not to
use it for any purpose. All subject/patient medical records shall remain the property of Institution. Each of Company and Institution shall retain records of the Study, including in Institution’s case either the original or a copy of all
volunteer consent forms, in conformance with federal regulations applicable to it. Institution shall also make such records available upon request for review by representatives of the U.S. Food and Drug Administration. Company acknowledges that
Company may not direct the manner in which Institution fulfills its obligations to permit inspection by governmental entities. It shall not be a breach of this Agreement for Institution to comply with the demands and requests of any
governmental entity in accordance with Institution’s judgment or to fail to inform and consult with Company before complying with any such demand or request. 

Section 8: Confidential Information 

8.1    Provision of Confidential Information. It is anticipated that in the performance of the Study Principal
Investigator, Company and Institution may need to disclose to each other information, which is considered confidential and proprietary. A Party may provide Confidential Information Party (“Discloser”) to the other Party
(“Recipient”); provided that Company shall only disclose Company Confidential Information to persons who are designated in writing by the Principal Investigator as being authorized to receive Confidential Information (collectively with the
Principal investigator, the “Institution Personnel”). The rights and obligations of the Parties with respect to Confidential Information are as follows: 

8.2    Definition. For the purposes of this Agreement, “Confidential Information” refers to information
of any kind, other than data from or results of the Study, that satisfies all of the following: (i) such information is disclosed by Discloser to Recipient, (ii) such information by appropriate marking, is identified as confidential at the
time of disclosure, and (iii) the disclosure of such information is necessary for a Party to exercise its rights or perform its obligations under this Agreement. In the event that Confidential Information must be provided visually or orally,
obligations of confidence shall attach only to that information that is confirmed by Discloser in writing within ten (10) working days of provision as being confidential. 

 8.3    Period of Restriction. For a period of five (5) years
after the Effective Date of this Agreement, Recipient agrees to use reasonable efforts, no less than the protection given its own confidential information, to use Confidential Information received from Discloser and accepted by Recipient only in
accordance with this Section 8. 
 8.4     Use of Confidential Information. Institution agrees and shall
require each member of the Institution Personnel to agree to use Company Confidential Information solely for the purposes of conducting the Study, obtaining any required review of the Study or its conduct, or ensuring proper medical treatment of any
patient or subject. Company agrees and shall require any of its employees with whom such information is shared to agree, to use Institution Confidential Information solely to exercise Company’s rights or perform Company’s obligations
hereunder. Company acknowledges and agrees that (i) Institution is an academic medical center in which the free exchange of information is actively encouraged among staff and researchers and (ii) Institution’s obligations with respect
to Company Confidential Information under this Section 8 (including subsections) shall apply only to disclosures thereof made to the applicable members of the Institution Personnel and not to disclosures thereof to any other person associated
with Institution or any of its affiliates 
 8.5    Release of Confidential Information. Except as provided
herein, Recipient agrees to keep all Confidential Information confidential unless Discloser gives specific written consent for release 

8.6    Notice of Unauthorized Disclosure. Recipient shall notify Discloser of any disclosure not authorized
hereunder of which it becomes aware. In such situations, Recipient shall take reasonable steps to prevent any further disclosure or unauthorized use. 

8.7    Exclusions. No Recipient shall be required to treat any information as Confidential Information under this
Agreement in the event: 
  

	 	(i)	 it is publicly available prior to the date of the Agreement or becomes publicly available thereafter through no
wrongful act of any Recipient; 

  

	 	(ii)	 it was known to any Recipient prior to the date of disclosure or becomes known to any Recipient thereafter from
a third party having an apparent bona fide right to disclose the information; 

  

	 	(iii)	 it is disclosed by any Recipient in accordance with the terms of Discloser’s prior written approval;

	 	(iv)	 it is disclosed by Discloser without restriction on further disclosure; 

 

	 	(v)	 it is independently developed by any Recipient; 

 

	 	(vi)	 it is necessary to disclose for patient treatment, patient safety or to prevent imminent harm to the public or,

  

	 	(vii)	 any Recipient is obligated to produce it pursuant to a requirement of applicable law or an order of a court of
competent jurisdiction or a facially valid administrative, Congressional or other subpoena, provided that the Recipient subject to the requirement or order or subpoena (A) promptly notifies Discloser and (B) cooperates reasonably with
Discloser’s efforts to contest or limit the scope of such disclosure. 

 8.8    Each Party
reserves the right, in its sole discretion and without prior notice to any other Party, to disclose its own Confidential Information to any third party for any purpose. 

Section 9: Budget 

9.1    General. Company agrees to support this Study with a research budget and payment schedule attached hereto as
Exhibit B and incorporated by reference herein. Institution shall monitor expenditures, in accordance with its policies, to ensure that the funds provided by Company are spent in accordance with this Agreement and approved budgets.
Institution agrees to use the funding provided under this Agreement solely for the purposes of carrying out the Study. 

9.2    Budget. Checks shall be made payable to “Dana Farber/Partners CancerCare, Inc.” Federal Tax ID# 04-3320640, shall reference the name of the Principal Investigator, the Protocol number and shall be forwarded to: 

Dana-Farber/Cancer Institute 

450 Brookline Ave, BP2102 

Boston, MA 02215 
 Attn: James R.
Huse 
 9.3    Clinical Care Procedures. Company acknowledges that the budget for the Study has been negotiated
in good faith and that any items and services specified in the Study Protocol that are for the clinical care of the Study subject (specifically, conventional care items and services as well as items and services to detect or prevent complications)
are eligible for third party reimbursement. Company shall treat all patient specific billing information as individually identifiable health information subject to the HIPAA protections in Section 3.2. Further, Company shall treat all
Institutional billing and financial information as Institutional Confidential Information subject to the protections in Section 8. 

 9.4    Compliance with Laws. The Parties shall comply with all
applicable laws, rules and regulations, including the federal Anti-Kickback Statute at 42 U.S.C. 1320a-7(b) and all applicable conditions of participation in governmental health care programs. In furtherance
thereof, the Parties hereto agree as follows: 
  

	 	(i)	 All services to be performed by Institution to or for the benefit of Company are and shall be as expressly set
forth in this Agreement. 

  

	 	(ii)	 The aggregate compensation payable to Institution pursuant to this Agreement is and shall be determined as
specifically set forth in this Agreement. 

  

	 	(iii)	 The rates of compensation for Institution’s services are and shall be consistent with the fair market
value of such services in the United States and have not been and shall not be determined in a manner which takes into account the volume or value of any referrals or business actually or potentially otherwise generated between Company and
Institution or any of Institution’s affiliates. 

  

	 	(iv)	 Nothing in this Agreement shall obligate Company or Institution to recommend or arrange for the products or
services offered by any Party, any affiliate thereof or any third party. 

 No Party or its affiliates shall request that
any other Party or its affiliates engage in any counseling or promotion of any business arrangement or other activity inconsistent with the requirements of applicable law. 
  

	 	(v)	 The services rendered by Institution shall be rendered solely to the extent reasonably necessary to address
areas of genuine clinical and research concern for which there is a legitimate need and purpose. 

  

	 	(vi)	 The decision by Company to engage Institution to conduct the Study pursuant to this Agreement has been made by
individuals qualified to evaluate the quality and integrity of Institution as a clinical trial site and without reference to the volume or value of any referrals or business otherwise actually or potentially generated between or among Company,
Institution, the Institution Personnel, or any of their respective affiliates. 

  

	 	(vii)	 If any part of this Agreement is determined to violate, or to be likely to violate, federal, state, or local
laws, rules, or regulations, the Parties agree to negotiate in good faith all reasonably necessary revisions to this Agreement to cure the violation or reduce the likelihood of the violation. If the Parties are unable to agree to new or modified
terms as required to bring the entire Agreement into compliance, either Party may terminate this Agreement. 

 Section 10: Term and Termination 

10.1    Term. The term of this Agreement shall be from the Effective Date until completion of the Parties’
substantive obligations under the Agreement in the performance of the Study, unless earlier terminated in accordance with Section 10.2. 

10.2    Termination. 

(a)    Either Party hereto shall have the right to terminate the Study and this Agreement at any time upon thirty
(30) days prior written notice thereof to the other Party. Either Party may terminate the Study and this Agreement at any time upon thirty (30) days prior written notice thereof to the other Party in the event of a material breach of the
Agreement by the other Party, and except that either Party may terminate the Study and this Agreement immediately upon written notice to the other Party if necessary to protect the health, welfare or safety of any Study subject. 

(b)    If the Principal Investigator ceases to serve in such role during the term of the Agreement, Institution shall
promptly notify Company. Institution may name a substitute principal investigator (who shall thereafter be referred to as Principal Investigator for purposes of this Agreement), subject to the approval of Company, which approval may be withheld in
Company’s sole discretion. If the Parties fail to reach agreement with respect to continuation of the Study and the Agreement within ninety (90) days following the date on which Institution notifies Company that the original Principal
Investigator became unavailable, Company shall have the right to terminate the Study and this Agreement immediately upon written notice to Institution. 

10.3    Continuation of Enrolled Patients. The Parties agree that if, at the time either Party receives notice of
termination pursuant to this section, any patients are enrolled in the Study, said patients shall complete the Study, at Company’s expense, if completion is in the best interest of said patients. 

10.4    Continuation of Grant. In the event of any termination other than a
for-cause termination by Company for Institution’s material breach, the amount of the research grant by Company to support the Study shall be appropriately prorated to allow Institution to recover
reasonable costs and non-cancellable commitments incurred, including without limitation, termination salary costs of any Institution personnel released as a result of such termination. 

10.5    Survival. The obligations of the Parties under Sections 1, 2, 3, 4, 5, 6.1, 7.1, 8, 9, 10.3, 10.4, 11,
13.2, and 13.4-13.7 shall survive any termination or expiration of this Agreement. 
 Section 11: Subject
Injury; Indemnification; and Insurance 
 11.1    Subject Injury. 

(a)    Company agrees to reimburse Institution for (or otherwise pay for) the costs of the care and treatment of any side
effect, adverse reaction, illness, or injury to a subject resulting from a defect in the Study Drug. 

(b)    Company’s subject injury commitment under (a) above shall not apply to any side effect, adverse reaction,
illness, or injury to the extent it directly results from: (i) the negligence or reckless or intentional misconduct of, or violation of law by, Institution, Principal Investigator, or Institution’s personnel; or (ii) failure of
Institution, Principal Investigator, or Institution’s personnel to adhere to the terms of the Protocol for the Study, provided, however, that emergency medical care shall not be deemed a violation of the Protocol. 

 11.2    Indemnification. 

(a)    Company will indemnify, defend and hold harmless, the Institution, its officers, agents, directors, trustees,
subsidiaries, affiliates, employees, students and members of its IRB, and their respective heirs, successors and assigns (collectively, “Institutional Indemnitees”) from and against any and all liability, damage, judgment, loss or expense
(including reasonable attorneys’ fees and costs) (“Liability”) that may be incurred by or imposed upon the Institutional Indemnitees or any of them in connection with any claim, suit, demand, action or judgment arising out of or
relating to the following: (i) the design, production, manufacture, labeling and/or shipment of the Study Drug; (ii) Company’s or Company’s affiliates, trustees, officers, professional staff, employees or agents (“Company
Persons”) use, non-use, interpretation, disclosure or publication of any of the Study Data, results and/or any intellectual property that results from or arises out of the Study; (iii) any negligence
or willful misconduct of Company or any Company Person, and (iv) a breach of Sponsor’s security leading to the accidental or unlawful destruction, loss, alteration, unauthorized disclosure, or access to individually identifiable health
information as defined by HIPAA. 
 (b)    Company’s indemnification under (a) above shall not apply to any
liability, damage, loss or expense to the extent that it is directly attributable to: (i) the negligence or reckless or intentional misconduct of, or violation of law by, the Indemnitees; or (ii) failure of the Indemnitees to adhere to the
terms of the Protocol for the Study, provided, however, that emergency medical care shall not be deemed a violation of the protocol. 

(c)    Company agrees, at its own expense, to provide attorneys reasonably acceptable to Institution to defend against any
actions brought or filed against any Party or individual indemnified hereunder with respect to the subject of the indemnity contained herein, whether or not such actions are rightfully brought. 

11.3    Insurance 

(a)    Company shall, at its sole cost and expense, procure and maintain policies of professional and general liability
insurance in amounts not less than Three Million Dollars ($3,000,000) per occurrence or claim and Five Million Dollars ($5,000,000) annual aggregate covering its obligations under this Agreement, including contractual liability coverage for its
subject injury and indemnification obligations. 
 (b)    Company shall provide Institution at its request with written
evidence of such insurance prior to the commencement of the Study. Company shall provide Institution with written notice at least thirty (30) days prior to the cancellation, non-renewal or material
change, in such insurance; if Company does not obtain replacement insurance providing comparable coverage within such thirty (30) day period, Institution shall have the right to terminate this Agreement effective at the end of such thirty
(30) day period without notice of any additional waiting periods. 

 Section 12: Notices 

12.1    Any written notices, reports, correspondences or other communications required under or pertaining to this
Agreement shall be given by prepaid, first class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed as follows: 

Institution: 
 Dana-Farber Cancer Institute 

Research Administration 
 450
Brookline Ave, BP2101 
 Boston, MA 02215 

Attn: Michael Rogers, JD 
 (T) 617-582-7844 
 Michael_Rogers@dfci.harvard.edu 

Company: 
 Kazia Therapeutics Limited 

L24, 300 Barangaroo Avenue, 

Sydney, NSW 2000 
 Australia 

Attn: Jeremy Simpson, PhD 
 (T)
+61 400 410 974 
 Jeremy.Simpson@kaziatherapeutics.com 

Section 13: Miscellaneous 

13.1    Amendment. The terms of this Agreement can be modified only by a writing, which is signed by authorized
representatives of Institution and Company. 
 13.2    Choice of Law; Jurisdiction and Venue. This Agreement
shall be governed by and construed and interpreted in accordance with the laws of the Commonwealth of Massachusetts. Each Party agrees to submit to the exclusive jurisdiction of the Superior Court for Suffolk County, Massachusetts, and the United
States District Court for the District of Massachusetts with respect to any claim, suit, or action in law or equity arising in any way out of this Agreement or the subject matter hereof. 

13.3    Assignment. Neither Party to this Agreement may assign its obligations hereunder without the prior written
consent of the other Party. 

 13.4    Entire Agreement. This Agreement, including any exhibits,
attachments, and other documents that are incorporated by reference herein, constitutes the entire understanding and agreement between the Parties, and supersedes and replaces all prior agreements, understandings, writings and discussions between
the Parties with respect to the subject matter of this Agreement. 
 13.5    Waiver. The failure of a Party in
any instance to insist upon the strict performance of the terms of this Agreement shall not be construed to be a waiver or relinquishment of any of the terms of the Agreement, whether at the time of the Party’s failure to insist upon strict
performance or at any time in the future, and such term(s) shall continue in full force and effect. 

13.6    Severability. Each clause of this Agreement is a distinct and severable clause and if any clause is deemed
illegal, void, or unenforceable, the validity, legality, or enforceability of any other clause of this Agreement will not be affected thereby. 

13.7.    Titles. All the titles and headings contained in the Agreement are inserted only as a matter of
convenience and reference and do not define, limit, extend, or describe the scope of this Agreement or the intent of any of its provisions. 

13.8    Counterpart Signatures. This Agreement, and any subsequent amendment(s), may be executed in counterparts
and the counterparts, together, shall constitute a single Agreement and shall become binding when any one or more counterparts hereof, individually or taken together, bears the signature of each of the parties hereto. A facsimile or e-mail delivery of a “.pdf” format data file of this Agreement signed by a party’s duly authorized representative shall be legal and binding on all parties. 

[SIGNATURE PAGE FOLLOWS] 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement through their duly
authorized representatives as of the Effective Date written above. 
  

							
	KAZIA THERAPEUTICS LTD	  	DANA-FARBER/PARTNERS CANCERCARE, INC.
				
	By:	 	                                     
                           	  	By:	  	                                     
                           
		 	          (duly authorized signatory)	  		  	          (duly authorized signatory)
		
	  
 Name: Dr James Garner

 
 Title: CEO

 
	  	  
 Name:

 
 Title:

	Date:	 	                                      
                          	  	Date:	  	                                      
                          
			
	 	 	 	  	 READ AND ACKNOWLEDGED:
  

PRINCIPAL INVESTIGATOR

				
	 	 	 	  	BY:	  	                                      
                          
	 	 	 	  	 	  	Dr. Lakshmi Nayak
				
	 	 	 	  	DATE:	  	
                          
                                      

 

 EXHIBIT A 

PROTOCOL 
 To be appended. 

 EXHIBIT B 

BUDGET AND PAYMENT SCHEDULE 
  

									
	 Execution of contract and IRB approval
	  	 	20.00	% 	 	$	                 	 
	 First patient dosed
	  	 	10.00	% 	 	$	 	 
	
10th Patient dosed
	  	 	25.00	% 	 	$	 	 
	
20th Patient dosed
	  	 	25.00	% 	 	$	 	 
	 Last patient in
	  	 	10.00	% 	 	$	 	 
	 Final Study Report
	  	 	10.00	% 	 	$	 	 
	 Total Budget
	  	 	100.00	% 	 	$	 	 

 1. Payments will be issued within 30 days of receipt of invoice. Payments must clearly identify invoice number,
protocol identifier, and DFCI PI. 
 2. If full enrollment is not achieved, payments will be made for all expenses reasonably incurred to the
date of termination in accordance with the Budget and with the terms of the Agreement. 

 EXHIBIT C 

RESPONSIBILITIES 

Responsibilities - Phase 2 Clinical Study 

Paxalisib (GDC-0084) 15mg Capsules 

Background & Scope: 
  

	 	(i)	 Institution plans to Sponsor a Phase 2 clinical study with GMP responsibilities as indicated below.

  

	 	(ii)	 Company will supply to Institution GMP manufactured and primary packed Study Drug (Investigational Medicinal
Product - IMP) for Phase 2 clinical trial use in the US under Dana-Farber Protocol. 

  

	 	(iii)	 GMP responsibilities of the parties are as indicated below. 

 

							
				
	 #
	  	 Responsibility
	  	Company	  	Institution
	 1
	  	IMP: Supply of GMP manufactured and primary packed (labeled) Study Drug Paxalisib (GDC-0084) 15mg capsules, 35 capsules per bottle, (active only, no placebo) with supporting GMP
documentation (e.g. manufacturers CoA)	  	X	  	
				
	 2
	  	IMP: Each bottle of Study Drug supplied will be labelled with unique lot number to prevent risk of mix-up	  	X	  	
				
	 3
	  	Retest Date & Storage Conditions: Provision of retest date(s) and storage conditions for the Study Drug supplied	  	X	  	
				
	 4
	  	IMP Ordering: Requests for Study Drug shipment will be provided to Company in writing	  		  	X
				
	 5
	  	Shipping: Will ship Study Drug to Institution accompanied by relevant paperwork (e.g. packing list)	  	X	  	
				
	 6
	  	Receipt & Labelling: Receive and store Study Drug for clinical trial use	  		  	X
				
	 7
	  	Release of IMP: responsibility for release of labelled Study Drug for Phase 2 clinical trial use in US	  	X	  	
				
	 8
	  	Product Defects / Product Complaints: will promptly notify the other party if a Product Quality Defect is observed or reported (e.g. damaged Study Drug capsules or primary packaging)	  	X	  	X
				
	 9
	  	Product Recall: Company are overall responsible for any product recall decision. Company will notify Institution in the event of a Product Recall and both parties will work together as may be required to coordinate both
the Recall activities and notifications to the relevant regulatory authorities as may be applicable [Note: Product Recall may also be referred to as “stock recovery” in certain territories (e.g. US) as the Sponsor exerts direct control
over the drug].	  	X	  	X
				
	 10
	  	Returns & Destruction: Responsibility for any returns and destruction rests with [Note: the process for destruction to be agreed with Company]	  		  	X

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]